Indoco Remedies is a vertically integrated pharmaceutical company that develops, manufactures, and sells generic drug formulations and active pharmaceutical ingredients (APIs) for both the Indian domestic market and international regulated markets like the US and Europe.
The company lacks a durable moat as evidenced by an average ROCE of 10.2%, which barely covers its cost of capital. While it has strong brand recognition in specific Indian niches like stomatology, its international business is a price-taking generic operation frequently disrupted by regulatory compliance issues and high remediation costs.
Capital allocation has been poor, characterized by heavy investment in a US sterile facility that has remained under a regulatory cloud for years, leading to high debt levels (D/E 1.16) and an interest coverage ratio of only 0.13. Recent moves include hiving off the ophthalmic business to Sunways to pare debt.
The company's collapse was driven by a liquidity trap where operating profits failed to cover rising interest obligations, exacerbated by a permanent regulatory shutdown of the Goa sterile facility. Management's inability to resolve USFDA warnings led to a total loss of international credibility, while the domestic business stagnated under the weight of stretched working capital and unpaid suppliers. The eventual fire sale of core brands to service debt left shareholders with a hollowed-out shell of a business that could no longer compete in a low-margin generic market.
RichFakir rates Indoco Remedies Ltd's business quality as poor — 18/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Indoco Remedies Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Indoco Remedies Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Indoco Remedies Ltd's fair value is about ₹96 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →